XML 252 R60.htm IDEA: XBRL DOCUMENT v3.20.1
REVENUE Disaggregated Revenue Table (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Dec. 31, 2019
Disaggregation of Revenue [Line Items]      
Accounts Receivable, Allowance for Credit Loss $ 28.9   $ 19.0
Unbilled Services, Allowance for Credit Loss 2.4   2.3
Note Receivable, Allowance for Credit Loss 10.0   0.0
Allowance for Credit Loss 41.3   21.3
Current Expected Credit Losses Opening Balance Sheet Impact on Retained Earnings 7.0    
Accounts Receivable, Credit Loss Expense (Reversal) 8.5    
Unbilled Services, Credit Loss Expense (Reversal) 0.0    
Note Receivable, Credit Loss Expense (Reversal) 5.0    
Credit Loss Expense (Reversal) 13.5    
Allowance for Credit Loss, Write Off 0.5    
Increase Decrease in Operating Income Loss $ (17.0)    
Sales Commission Amortization Period Minimum 12 months    
Deferred Revenue, Revenue Recognized $ 121.8 $ 103.6  
Contract with Customer, Asset, before Allowance for Credit Loss 480.6   483.7
Revenue, Remaining Performance Obligation, Amount $ 4,494.9    
Percent of remaining performance obligations recognized as revenue in next year 35.00%    
Long Term Contracts Duration Minimum 1 year    
Long Term Contracts Duration Maximum 8 years    
Contract with Customer, Performance Obligation Satisfied in Previous Period $ 9.7 39.7  
Contract with Customer, Liability 430.9   449.2
Capitalized Contract Cost, Amortization 3.0 1.8  
Accrued Sales Commission 30.3   28.6
Capitalized Contract Cost, Net 13.8   14.9
Amount of Deferred Costs Related to Long-term Contracts 44.1   43.5
Amortization of Deferred Sales Commissions 5.3 $ 4.5  
Unbilled Contracts Receivable $ 478.1   481.4
Percent of Revenue Contributed 100.00% 100.00%  
Sales Commission Amortization Period Maximum 57 months    
Medicare and Medicaid [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 8.00% 9.00%  
UNITED STATES      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 77.00% 78.00%  
CANADA      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 3.00% 3.00%  
UNITED KINGDOM      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 5.00% 4.00%  
SWITZERLAND      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 5.00% 5.00%  
Europe [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 3.00% 3.00%  
Other countries [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 7.00% 7.00%  
LabCorp Diagnostics [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 60.00% 62.00%  
LabCorp Diagnostics [Member] | Client [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 17.00% 17.00%  
LabCorp Diagnostics [Member] | Self-Pay [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 7.00% 8.00%  
LabCorp Diagnostics [Member] | Third party [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 28.00% 28.00%  
LabCorp Diagnostics [Member] | UNITED STATES      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 57.00% 59.00%  
LabCorp Diagnostics [Member] | UNITED STATES | Client [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 16.00% 16.00%  
LabCorp Diagnostics [Member] | UNITED STATES | Self-Pay [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 7.00% 8.00%  
LabCorp Diagnostics [Member] | UNITED STATES | Medicare and Medicaid [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 8.00% 9.00%  
LabCorp Diagnostics [Member] | UNITED STATES | Third party [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 26.00% 26.00%  
LabCorp Diagnostics [Member] | CANADA      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 3.00% 3.00%  
LabCorp Diagnostics [Member] | CANADA | Client [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 1.00% 1.00%  
LabCorp Diagnostics [Member] | CANADA | Self-Pay [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 0.00% 0.00%  
LabCorp Diagnostics [Member] | CANADA | Medicare and Medicaid [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 0.00% 0.00%  
LabCorp Diagnostics [Member] | CANADA | Third party [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 2.00% 2.00%  
LabCorp Diagnostics [Member] | UNITED KINGDOM      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 0.00% 0.00%  
LabCorp Diagnostics [Member] | UNITED KINGDOM | Client [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 0.00% 0.00%  
LabCorp Diagnostics [Member] | UNITED KINGDOM | Self-Pay [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 0.00% 0.00%  
LabCorp Diagnostics [Member] | UNITED KINGDOM | Medicare and Medicaid [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 0.00% 0.00%  
LabCorp Diagnostics [Member] | UNITED KINGDOM | Third party [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 0.00% 0.00%  
LabCorp Diagnostics [Member] | SWITZERLAND      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 0.00% 0.00%  
LabCorp Diagnostics [Member] | SWITZERLAND | Client [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 0.00% 0.00%  
LabCorp Diagnostics [Member] | SWITZERLAND | Self-Pay [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 0.00% 0.00%  
LabCorp Diagnostics [Member] | SWITZERLAND | Medicare and Medicaid [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 0.00% 0.00%  
LabCorp Diagnostics [Member] | SWITZERLAND | Third party [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 0.00% 0.00%  
LabCorp Diagnostics [Member] | Europe [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 0.00% 0.00%  
LabCorp Diagnostics [Member] | Europe [Member] | Client [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 0.00% 0.00%  
LabCorp Diagnostics [Member] | Europe [Member] | Self-Pay [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 0.00% 0.00%  
LabCorp Diagnostics [Member] | Europe [Member] | Medicare and Medicaid [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 0.00% 0.00%  
LabCorp Diagnostics [Member] | Europe [Member] | Third party [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 0.00% 0.00%  
LabCorp Diagnostics [Member] | Other countries [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 0.00% 0.00%  
LabCorp Diagnostics [Member] | Other countries [Member] | Medicare and Medicaid [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 0.00% 0.00%  
LabCorp Diagnostics [Member] | Other countries [Member] | Third party [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 0.00% 0.00%  
Covance Drug Development [Member]      
Disaggregation of Revenue [Line Items]      
Unbilled Contracts Receivable $ 758.6   $ 771.1
Percent of Revenue Contributed 40.00%    
Covance Drug Development [Member] | Biopharmaceutical and medical device companies [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 40.00% 38.00%  
Covance Drug Development [Member] | UNITED STATES | Biopharmaceutical and medical device companies [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 20.00% 19.00%  
Covance Drug Development [Member] | CANADA | Biopharmaceutical and medical device companies [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 0.00% 0.00%  
Covance Drug Development [Member] | UNITED KINGDOM | Biopharmaceutical and medical device companies [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 5.00% 4.00%  
Covance Drug Development [Member] | SWITZERLAND | Biopharmaceutical and medical device companies [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 5.00% 5.00%  
Covance Drug Development [Member] | Europe [Member] | Biopharmaceutical and medical device companies [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 3.00% 3.00%  
Covance Drug Development [Member] | Other countries [Member] | Biopharmaceutical and medical device companies [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 7.00% 7.00%  
Minimum [Member]      
Disaggregation of Revenue [Line Items]      
Capitalized Contract Cost, Amortization Period 24 months    
Maximum [Member]      
Disaggregation of Revenue [Line Items]      
Capitalized Contract Cost, Amortization Period 60 months    
Notes Receivable [Member]      
Disaggregation of Revenue [Line Items]      
Current Expected Credit Losses Opening Balance Sheet Impact on Retained Earnings $ 5.0    
Allowance for Credit Loss, Write Off 0.0    
Unbilled Contracts Receivable [Member]      
Disaggregation of Revenue [Line Items]      
Current Expected Credit Losses Opening Balance Sheet Impact on Retained Earnings 0.2    
Allowance for Credit Loss, Write Off 0.1    
Accounts Receivable [Member]      
Disaggregation of Revenue [Line Items]      
Current Expected Credit Losses Opening Balance Sheet Impact on Retained Earnings 1.8    
Allowance for Credit Loss, Write Off $ 0.4